Blood and blood components
Find out how blood and blood components are regulated.
Blood and blood components including haematopoietic progenitor cells and plasma-derived medical products are regulated as prescription medicines under the Therapeutic Goods (Manufacturing Principles) Determination.
- blood means whole blood collected from a single human donor and processed either for transfusion or further manufacturing
- blood components means therapeutic components of blood (red cells, white cells, platelets, plasma) that can be prepared by centrifugation, filtration and freezing, but not including haematopoietic progenitor cells
- plasma derived products (or that contain plasma derived products)
- recombinant products
- haematopoietic progenitor cells (HPC) used for haematopoietic reconstitution:
- HPC means self-renewing or multi-potent stem cells, or both, capable of maturation into haematopoietic lineages, lineage-restricted pluripotent progenitor cells, or committed progenitor cells.
- Includes HPC derived from cord blood.
Latest articles
-
GMP surveillance inspections and extended validity of TGA GMP certificates
Information for manufacturers and sponsors regarding a new method for GMP inspections that will be used from 1 July 2024 and the extended validity of TGA issued GMP Certificates. -
Stem cell treatments and regulation - a quick guide for consumers
Commonly asked questions about stem cells and regulation
This webpage on the TGA website was printed on 14 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/products/biologicals-blood-and-tissues-and-advanced-therapies/blood-and-blood-components